{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:34:00Z","timestamp":1793050440421,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":44,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtho.2026.104202","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:41:15Z","timestamp":1789627275000},"page":"104202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced NSCLC in a Phase 2 Study"],"prefix":"10.1016","author":[{"given":"Todd M.","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Riely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Toffalorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Usari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phineas","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3059-5730","authenticated-orcid":false,"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.104202_bib1","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.jtho.2026.104202_bib2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104202_bib3","series-title":"FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC. CMR","year":"2018"},{"key":"10.1016\/j.jtho.2026.104202_bib5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2026.104202_bib6","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib7","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib8","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jtho.2024.11.021","article-title":"Final overall survival and long-term safety of lorlatinib in patients with ALK-positive NSCLC from the pivotal phase 2 study: a brief report","volume":"20","author":"Ou","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib10","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib11","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","article-title":"ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer","volume":"4","author":"Solomon","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","article-title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC","volume":"158","author":"Zhang","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.104202_bib13","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2024.07.009","article-title":"Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: real-world outcomes from the GuardantINFORM database","volume":"19","author":"Parikh","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib15","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920980558","article-title":"Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program","volume":"13","author":"Frost","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib17","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib18","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.104202_bib19","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jtho.2023.05.021","article-title":"Early circulating tumor DNA dynamics and efficacy of lorlatinib in patients with treatment-naive, advanced, ALK-positive NSCLC","volume":"18","author":"Soo","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib20","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/0008-5472.CAN-21-1903","article-title":"Clonal hematopoiesis mutations in patients with lung cancer are associated with lung cancer risk factors","volume":"82","author":"Hong","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.104202_bib22","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/2159-8290.CD-24-0231","article-title":"NVL-655 Is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations","volume":"14","author":"Lin","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.104202_bib23","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.1016\/j.annonc.2024.08.1310","article-title":"1253O Phase I\/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours","volume":"35","author":"Drilon","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib24","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/annonc\/mdx212","article-title":"Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study","volume":"28","author":"Cabel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.104202_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12967-019-2051-8","article-title":"Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy","volume":"17","author":"Seremet","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.jtho.2026.104202_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230622","article-title":"Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation","volume":"15","author":"Cho","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2026.104202_bib27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","article-title":"Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond","volume":"124","author":"Keller","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2026.104202_bib28","article-title":"Diagnostic accuracy of circulating tumor DNA for detection of ALK rearrangement in lung cancer: a systematic review and meta-analysis of 14 studies","volume":"20","author":"Sun","year":"2025","journal-title":"PLoS One"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426006556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426006556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:38:58Z","timestamp":1793047138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426006556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S1556086426006556"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104202","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced NSCLC in a Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"104202"}}